Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alpha Tau Medical Ltd ( (DRTS) ) has issued an announcement.
On May 6, 2025, Alpha Tau Medical Ltd. announced its participation in two investor conferences in May 2025. CFO Raphi Levy will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York on May 20 and participate in the Lytham Partners Spring 2025 Investor Conference virtually on May 29. These engagements highlight Alpha Tau’s ongoing efforts to engage with investors and showcase its innovative cancer therapy technology, potentially impacting its market presence and stakeholder interest.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Underperform.
Alpha Tau Medical Ltd is struggling with significant financial challenges, primarily due to a lack of revenue and ongoing cash burn. While technical indicators show a neutral trend, the valuation metrics reflect the company’s unprofitability. The absence of earnings call insights and corporate events limits additional context. Overall, the stock is risky with a low score of 38, suggesting caution for potential investors.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of the Alpha DaRT technology for treating solid tumors. The Alpha DaRT, or Diffusing Alpha-emitters Radiation Therapy, is designed to deliver highly potent alpha-irradiation directly to solid tumors, minimizing damage to surrounding healthy tissue.
Average Trading Volume: 45,885
Technical Sentiment Signal: Sell
Current Market Cap: $219.3M
Learn more about DRTS stock on TipRanks’ Stock Analysis page.